International Diabetes Federation

www.idf.org
Brussels, Belgium

The International Diabetes Federation is a worldwide alliance of over 230 national diabetes associations in more than 160 countries, who have come together to enhance the lives of people with diabetes everywhere. The Federation is committed to raising global awareness of diabetes, promoting appropriate diabetes care and prevention, and encouraging activities towards finding a cure for the different types of diabetes. The Federation has been leading the global diabetes community since 1950. It is headquartered in Brussels, Belgium.IDF is divided into seven regions, with the aim of strengthening the work of national diabetes associations and enhancing the collaboration between them. IDF’s national diabetes associations are divided into the following regions: Africa ,Europe ,Middle East and North Africa , North America and Caribbean ,South and Central America , South East Asia and Western Pacific .IDF’s working bodies bring together the most important stakeholders from the global diabetes community in a collaborative effort to set common goals and co-ordinate activities towards the attainment of these goals. These stakeholders include: people with diabetes and their families; professionals involved in diabetes healthcare and related fields; diabetes representative organizations, and partners from commercial organizations with concerns which align with the mission of the Federation. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization and the Pan American Health Organization.According to the latest IDF figures, there are currently 382 million people living with diabetes and the total is expected to rise to 592 million by 2035. Some 80% of people with diabetes live in low- and middle-income countries and almost half of people living with diabetes are undiagnosed. Wikipedia.


Time filter

Source Type

News Article | May 17, 2017
Site: co.newswire.com

Iranian knowledge-based firm Daru Darman has unveiled a new herbal medicine for diabetic wounds Derma Heal, an herbal ointment used for diabetic ulcer treatment, facilitates the removal of damaged textures in diabetic wounds and helps patients save their legs by preventing the infection of such ulcers. A typical person walks about 3 miles per day. The human body needs energy for walking, thinking, and doing daily activities, and this energy is supplied by eating. Sugar, or glucose, is the most important source of energy for cells in the human body. If the level of glucose in one’s blood decreases, it can lead to a loss of consciousness, coma, and finally death within a few hours. However, the excessive increase of glucose in the human body is more common. The excess glucose in the blood should be rapidly turned to glycogen through the secretion of a hormone called insulin. If a person’s body loses the ability to regulate the amount of blood sugar, that person suffers from diabetes. According to the International Diabetes Federation (IDF), in 1985, 30 million people in the world suffered from diabetes. The figure rose to 230 million in 2008. Currently, two people in the world develop diabetes every 10 seconds. Unhealthy diets and incorrect lifestyles have turned diabetes into a serious crisis around the world. Diabetes is the most costly endocrine disease in the world. Studies indicate that nearly 400 million are currently suffering from diabetes. However, money is probably the least important thing a person diagnosed with diabetes may lose. After a while, the disease leads to low vision, blindness, and even loss of limbs. According to the IDF, 2,880 people lose their legs every day, and their ability to walk is undermined for the rest of their lives. … But this is not the end of the story. Those suffering from diabetes can still save their legs. Until 150 years ago, there was no chemical medicine; doctors used to prescribe medicinal herbs for their patients. Arnebia euchroma L is one of those medicinal herbs, which has been used throughout the history in healing dangerous wounds. Thanks to Iran’s ecological features and age-old history in traditional medicine and herbal remedies, grounds are prepared in the country for conducting specialized scientific research on the treatment of various diseases through identification and production of medicinal herbs. Daru Darman Salafchegan Company, as a knowledge-based producer of herbal medicine in Iran, has managed to produce an herbal ointment named “Derma Heal.” “Derma Heal,” an ointment produced from the roots of Arnebia euchroma L plant, facilitates the removal of damaged textures in diabetic ulcers, and helps the new texture replace the dead ones by stimulating the production of more cells. The ointment also has considerable anti-bacterial and anti-fungal impacts, and not only prevents the infection of diabetic ulcers, but also helps the patients save their legs. Derma Heal accelerates the diabetic ulcer treatment process and also sharply reduces the patients' costs. The company has passed all clinical tests and obtained the required licenses for the ointment at the international level. It is now prepared to sign deals with applicant companies across the world, offering its herbal products based on (up to) two-year usance contracts. Let’s join hands to change the future, so that no one would have to lose a leg because of diabetes.


News Article | April 21, 2017
Site: marketersmedia.com

— The global pen needles market is expected to reach a value of USD 4.8 billion by 2025, according to a new report by Grand View Research, Inc. Rising prevalence of diabetes is the primary reason for the significant growth of pen needles market. According to the International Diabetes Federation (IDF), nearly 415 million people were suffering from diabetes in 2015. Such a high prevalence of diabetes across the globe has led to rising demand for pen needles. Patients suffering from diabetes commonly use injectable pen devices, which helps in easy drug delivery. In addition, obesity is a significant cause of diabetes. Obese people often suffer from type 2 diabetes, which makes them one of the highest revenue contributors of the target market. Thus, people with type 2 diabetes are the common target population for companies manufacturing pen needles. Rising technological advancements is also expected to drive the market growth. Pen needles allow comfort and easy mode of insulin delivery. These devices are technologically advanced and provide a superior alternative drug delivery method in comparison to syringes and vials. For instance, in 2013, Becton, Dickinson and Company launched BD Ultra-Fine Nano 4mm Pen Needles with EasyFlow Technology, which will enable diabetic patients with easy adherence of insulin therapy regimens. Further Key Findings from the Study Suggest: Standard needles dominated the market in 2015 due to the availability of cost-effective needles as compared to safety needles. Safety pen needles are anticipated to showcase lucrative growth over the forecast period due to the continuous technological advancements. Amongst the needle lengths, 8mm held the largest share in 2015. This is due to the convenience offered by this needle type on diabetic patients. Needle length of 4mm are expected to witness attractive CAGR over the forecast period owing to its short length. Insulin therapy accounted for the largest market share in 2015 due to rising awareness regarding self-administration of insulin amongst the diabetic patients. Europe dominated the market in 2015 followed by North America owing to high prevalence of diabetes in the European region. Asia Pacific region is anticipated to exhibit the highest growth rate over the forecast period owing to the rising awareness levels amongst the diabetic population regarding easy drug delivery. Some of the key players include Becton, Dickinson and Company, B. Braun Melsungen AG, Novo Nordisk A/S, Owen Mumford, Ltd., Ypsomed, HTL-STREFA, and TERUMO CORPORATION. Chapter One: Research Methodology Chapter Two: Executive Summary Chapter Three: Pen Needles Market Variables, Trends & Scope Chapter Four: Pen Needles: Product Estimates & Trend Analysis Chapter Five: Pen Needles: Needle Length Estimates & Trend Analysis Chapter Six: Pen Needles: Therapy Estimates & Trend Analysis Chapter Seven: Pen Needles: Regional Estimates & Trend Analysis, by Product, Needle Length, Therapy Chapter Eight: Competitive Landscape About Us: Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients. For more information, please visit http://www.orbisresearch.com/reports/index/pen-needles-market-analysis-by-product-standard-pen-needles-safety-pen-needles-by-needle-length-4mm-5mm-6mm-8mm-10mm-12mm-by-therapy-insulin-glucagon-like-peptide-1-glp-1-growth-hormone-and-segment-forecasts-2014-2025


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Pen Needles Market, 2014 - 2025" report to their offering. The global pen needles market is expected to reach a value of USD 4.8 billion by 2025. Rising prevalence of diabetes is the primary reason for the significant growth of pen needles market. According to the International Diabetes Federation (IDF), nearly 415 million people were suffering from diabetes in 2015. Such a high prevalence of diabetes across the globe has led to rising demand for pen needles. Patients suffering from diabetes commonly use injectable pen devices, which helps in easy drug delivery. In addition, obesity is a significant cause of diabetes. Obese people often suffer from type 2 diabetes, which makes them one of the highest revenue contributors of the target market. Thus, people with type 2 diabetes are the common target population for companies manufacturing pen needles. Rising technological advancements is also expected to drive the market growth. Pen needles allow comfort and easy mode of insulin delivery. These devices are technologically advanced and provide a superior alternative drug delivery method in comparison to syringes and vials. For instance, in 2013, Becton, Dickinson and Company launched BD Ultra-Fine Nano 4mm Pen Needles with EasyFlow Technology, which will enable diabetic patients with easy adherence of insulin therapy regimens. For more information about this report visit http://www.researchandmarkets.com/research/gkjxwj/pen_needles


Smart Insulin Pens Market Poised for Robust CAGR of Over 17.9% Through 2027 Future Market Insights has announced the addition of the "Smart Insulin Pens Market: Global Industry Analysis and Opportunity Assessment 2017-2027" report to their offering. Valley Cottage, NY, April 29, 2017 --( By connectivity, the Bluetooth connected smart insulin pen segment is expected to account for a value share of US$ 0.276 Mn in 2017. The segment is expected to reach a little more than US$ 2 Mn by 2027 end, registering the highest CAGR of 23.2% over the forecast period. Bluetooth connected smart insulin pens represent the future of insulin delivery devices. Such devices have an inbuilt Bluetooth connectivity feature allowing automatic insulin dosage data sharing with healthcare providers. The contribution of the Bluetooth connected smart insulin pen connectivity segment to the overall smart insulin pens market revenue is expected to increase from more than 30% in 2017 end to close to 50% by the end of 2027, with an increase of more than 1000 BPS. The USB connected smart insulin pen segment is estimated to create an absolute $ opportunity of US$ 0.090 Mn in 2018 over 2017. Revenue from the USB connected smart insulin pen segment is anticipated to expand at a CAGR of 14.4% over 2017–2027, to reach more than US$ 2 Mn by 2027. Pendiq smart insulin pen is the only available USB connected smart insulin pen in the European market. Most of the companies in the global smart insulin pens market are focussing on developing Bluetooth enabled smart insulin pens; therefore, the Bluetooth connected smart insulin pen segment is expected to occupy a majority of the market share during the projected period. Request For Sample @ http://www.futuremarketinsights.com/reports/sample/rep-gb-1827 Increasing demand for improved diabetes management is expected to boost the market value of USB and Bluetooth enabled smart insulin pens. Increasing prevalence of diabetes is one of the growing concerns currently. According to the International Diabetes Federation, an estimated 415 million people were suffering from diabetes in 2015. This is projected to reach 642 million by 2040. Therefore, daily insulin dose management among diabetic patients is important in order to better manage the disease leading to rapid penetration of smart insulin pen technology in the global market. Smart insulin pens have transformed diabetes care through digitalisation and connectivity. A rapidly increasing diabetic patient pool is expected to create a positive impact on the Bluetooth connected smart insulin pen segment. Diabetes management with conventional insulin pens available in the market is tedious, time-consuming and requires patients to remember and document their data, making it difficult for them to manage their insulin dosage in a timely manner, and can lead to a misinterpretation of the results. Bluetooth and USB enabled smart insulin pens allow users to track their insulin doses and facilitate seamless documentation of insulin units and blood glucose levels. Smart insulin pens also send alerts to patients and healthcare professionals in case of missed doses. This is attributed to an increasing number of manufacturers focussing on introducing devices with smart connectivity, which allow automatic insulin dose data transfer on the patient portal for streamlined data dosage management. Send An Enquiry @ http://www.futuremarketinsights.com/askus/rep-gb-1827 Needle stick injuries with diabetes injection needles and lancing devices are a key concern for diabetics. Insulin syringe needle stick injuries is a percutaneous wound injury caused by needle tips and can occur while using, handling, disassembling, or disposing of needles and syringes. High incidence rate of needle stick injuries and associated serious consequences persuade healthcare professionals to use injection pens. This is expected to augment the penetration of Bluetooth and USB enabled smart insulin pens in the global smart insulin pens market. Bluetooth connected smart insulin pen segment is expected to witness 4.9X growth in terms of revenue contribution in the Asia Pacific smart insulin pens market. Bluetooth connected smart insulin pen segment is estimated to register the highest attractiveness index of 1.5 as compared to the USB connected smart insulin pen segment in the global market during the forecast period. This is due to the proliferation of Bluetooth connected smart insulin pens in the North America smart insulin pens market. Also, heavy investment by several big players to develop smart connected insulin pen devices is pushing the revenue generation of smart insulin pens in the North America smart insulin pens market. In Europe, the Bluetooth connected smart insulin pen segment is anticipated to register a market attractiveness index of 1.2 during the forecast period. USB connected smart insulin pen segment is expected to depict a market attractiveness index of 0.5 during the forecast period in the Asia Pacific region. India and China are the most populous countries in Asia Pacific with the highest number of patients diagnosed with diabetes. Increasing efforts by market players to expand their smart insulin pens business in Asia Pacific countries offer immense potential for revenue generation. Browse Full Report @ http://www.futuremarketinsights.com/reports/smart-insulin-pens-market Valley Cottage, NY, April 29, 2017 --( PR.com )-- Bluetooth connected smart insulin pen segment to register highest market attractiveness index in the near future.By connectivity, the Bluetooth connected smart insulin pen segment is expected to account for a value share of US$ 0.276 Mn in 2017. The segment is expected to reach a little more than US$ 2 Mn by 2027 end, registering the highest CAGR of 23.2% over the forecast period. Bluetooth connected smart insulin pens represent the future of insulin delivery devices. Such devices have an inbuilt Bluetooth connectivity feature allowing automatic insulin dosage data sharing with healthcare providers. The contribution of the Bluetooth connected smart insulin pen connectivity segment to the overall smart insulin pens market revenue is expected to increase from more than 30% in 2017 end to close to 50% by the end of 2027, with an increase of more than 1000 BPS.The USB connected smart insulin pen segment is estimated to create an absolute $ opportunity of US$ 0.090 Mn in 2018 over 2017. Revenue from the USB connected smart insulin pen segment is anticipated to expand at a CAGR of 14.4% over 2017–2027, to reach more than US$ 2 Mn by 2027. Pendiq smart insulin pen is the only available USB connected smart insulin pen in the European market. Most of the companies in the global smart insulin pens market are focussing on developing Bluetooth enabled smart insulin pens; therefore, the Bluetooth connected smart insulin pen segment is expected to occupy a majority of the market share during the projected period.Request For Sample @ http://www.futuremarketinsights.com/reports/sample/rep-gb-1827Increasing demand for improved diabetes management is expected to boost the market value of USB and Bluetooth enabled smart insulin pens.Increasing prevalence of diabetes is one of the growing concerns currently. According to the International Diabetes Federation, an estimated 415 million people were suffering from diabetes in 2015. This is projected to reach 642 million by 2040. Therefore, daily insulin dose management among diabetic patients is important in order to better manage the disease leading to rapid penetration of smart insulin pen technology in the global market. Smart insulin pens have transformed diabetes care through digitalisation and connectivity. A rapidly increasing diabetic patient pool is expected to create a positive impact on the Bluetooth connected smart insulin pen segment.Diabetes management with conventional insulin pens available in the market is tedious, time-consuming and requires patients to remember and document their data, making it difficult for them to manage their insulin dosage in a timely manner, and can lead to a misinterpretation of the results. Bluetooth and USB enabled smart insulin pens allow users to track their insulin doses and facilitate seamless documentation of insulin units and blood glucose levels. Smart insulin pens also send alerts to patients and healthcare professionals in case of missed doses. This is attributed to an increasing number of manufacturers focussing on introducing devices with smart connectivity, which allow automatic insulin dose data transfer on the patient portal for streamlined data dosage management.Send An Enquiry @ http://www.futuremarketinsights.com/askus/rep-gb-1827Needle stick injuries with diabetes injection needles and lancing devices are a key concern for diabetics. Insulin syringe needle stick injuries is a percutaneous wound injury caused by needle tips and can occur while using, handling, disassembling, or disposing of needles and syringes. High incidence rate of needle stick injuries and associated serious consequences persuade healthcare professionals to use injection pens. This is expected to augment the penetration of Bluetooth and USB enabled smart insulin pens in the global smart insulin pens market.Bluetooth connected smart insulin pen segment is expected to witness 4.9X growth in terms of revenue contribution in the Asia Pacific smart insulin pens market.Bluetooth connected smart insulin pen segment is estimated to register the highest attractiveness index of 1.5 as compared to the USB connected smart insulin pen segment in the global market during the forecast period. This is due to the proliferation of Bluetooth connected smart insulin pens in the North America smart insulin pens market. Also, heavy investment by several big players to develop smart connected insulin pen devices is pushing the revenue generation of smart insulin pens in the North America smart insulin pens market. In Europe, the Bluetooth connected smart insulin pen segment is anticipated to register a market attractiveness index of 1.2 during the forecast period. USB connected smart insulin pen segment is expected to depict a market attractiveness index of 0.5 during the forecast period in the Asia Pacific region. India and China are the most populous countries in Asia Pacific with the highest number of patients diagnosed with diabetes. Increasing efforts by market players to expand their smart insulin pens business in Asia Pacific countries offer immense potential for revenue generation.Browse Full Report @ http://www.futuremarketinsights.com/reports/smart-insulin-pens-market Click here to view the list of recent Press Releases from Future Market Insights


HOUSTON - (March 2, 2017) - The Robert Wood Johnson Foundation (RWJF) has awarded a three-year, $2.4 million grant to The University of Texas Health Science Center at Houston (UTHealth) to create the Healthy Cities Research Hub: Exploring Drivers of Diabetes and Other Chronic Diseases. The virtual research hub will focus on the social and environmental conditions that impact health in urban settings throughout North America, facilitating knowledge exchange and evaluating community-based interventions aimed at improving public health in cities. The grant is awarded at a time when the Type 2 diabetes epidemic is threatening to overwhelm health systems. As urban populations increase, aspects of city lifestyles such as long commutes and time pressure are increasing people's vulnerability to non-communicable diseases such as Type 2 diabetes. According to the International Diabetes Federation, 415 million people across the world have diabetes, two-thirds of whom are living in urban areas. The effort represents a unique collaboration with Novo Nordisk, a global health care company, through its Cities Changing Diabetes program, which was developed in partnership with University College London and the Steno Diabetes Center to understand the social and cultural factors behind vulnerability to diabetes in urban settings and reduce its severity in cities. Cities Changing Diabetes engages a range of local partners including diabetes and health organizations, city governments, academic institutions, city experts and civil society organizations. Eight cities across the world are part of the program. The Healthy Cities Research Hub will work in three North American cities that currently have Cities Changing Diabetes programs in place: Houston, Mexico City and Vancouver. The research hub, funded by RWJF, will focus on extracting and translating the findings from these community-led efforts and sharing the results to help other cities put them into action. This includes developing a framework that evaluates social and cultural factors of health in urban settings, driving action-oriented research, developing activities between researchers and local stakeholders to convert research into new activities and producing toolkits and good practices to inspire other cities. "This is an opportunity to extend the community-based work of the Cities Changing Diabetes initiative through new tools for evaluation and dissemination so that the results proven here can help other cities," said Stephen Linder, Ph.D., lead researcher of the project and director of the Institute for Health Policy at UTHealth School of Public Health. Linder has served as the lead researcher for Cities Changing Diabetes in Houston since the program began locally in 2014. As part of the new grant, he will also work with Cities Changing Diabetes lead researchers in Mexico City and Vancouver to foster collaboration and the exchange of knowledge, experience and insight across the three cities. "We're excited to draw out specific lessons from Cities Changing Diabetes' global work to inform our efforts to transform United States cities into places that enable everyone in our diverse society to lead healthier lives now and for generations to come," said Alonzo Plough, Ph.D., vice president of Research-Evaluation-Learning and chief science officer at the Robert Wood Johnson Foundation. "When we initiated Cities Changing Diabetes, our goal was to join forces with cities and community stakeholders to understand and address the urban diabetes challenge -- globally and locally," said Niels Lund, vice president of Health Advocacy at Novo Nordisk. "This collaboration with the Robert Wood Johnson Foundation and UTHealth is an important step forward in this effort and we are proud and honored to be part of it." The grant will also allow researchers to further develop Houston's adaptation of the Cities Changing Diabetes model, which could serve as a blueprint to inspire future cities and communities involved in the program. Co-investigators from UTHealth School of Public Health include Rebecca Wells, Ph.D., Dritana Marko, M.D., Jessica Tullar, Ph.D., and Ellen Breckenridge, Ph.D., J.D.


News Article | December 2, 2016
Site: www.theguardian.com

As our planet faces increasing urbanisation, public health experts are spearheading innovation for adjusting to this. We know that cities can make us ill: according to figures from the International Diabetes Federation, in 2014 there were 387 million people globally suffering from diabetes and in 2015 there were 415 million people living with the disease. Two-thirds of those people live in cities, experiencing poor diet and sedentary lifestyles. And our mental health suffers in cities, too. Urban living has been found to raise the risk of anxiety and mood disorders by 21% and 39% respectively. While half the world population currently lives in a city, this is predicted to rise to two-thirds by 2050. As they grow, cities will play a crucial role in finding solutions to many of our greatest public health challenges, from obesity and diabetes to communicable diseases like tuberculosis. With public health systems overstretched, and local governments pressed on all sides for resources and money, innovative solutions are needed. Public-private partnerships (PPPs) could be a source of new thinking, getting projects off the ground. So how can cities best build on PPPs to create health systems and fresh thinking so that our urban world will be a healthy one? How can public health bodies capitalise on the skills of the private sector without losing control? How can cities ensure equal access to healthcare for all residents? And what role should city mayors and other local government figures play in establishing innovative partnerships for health? Join an expert panel on Thursday 8 December, from 2pm to 3.30pm GMT, to discuss these questions and more. Niels Lund, vice president, Novo Nordisk and Cities Changing Diabetes spokesperson, Copenhagen, Denmark @lund_niels Cities Changing Diabetes is a programme to address the huge urban diabetes challenge. Niels has had an extensive career in international development with assignments for Unicef and the World Bank. Abdul El-Sayed, executive director and health officer, City of Detroit, United States @AbdulElSayed Abdul is turning around the fortunes of healthcare in one of America’s poorest cities, working with a variety of partners from all sectors. Laurence Carmichael, head, WHO Collaborating Centre for Healthy Urban Environments, UWE, Bristol, UK @laurencecarmich Laurence contributes to healthy cities research, consultancy and teaching in collaboration with local, national and international stakeholders including WHO-Europe. Julie Hughes, director, Institute for Market Transformation (IMT), co-director, City Energy Project, Washington DC, US The City Energy Project is a national initiative to create healthier and more prosperous American cities by improving the energy efficiency of buildings. IMT seeks market-based solutions to today’s climate and energy challenges. Susan Claris, associate director, transport consulting, Arup, London, UK, @Susan Claris Susan is a transport planner and anthropologist who has worked for Arup for more than twenty years. She has a particular interest in the many benefits that arise from making cities more walkable. Claudia Adirazola, director, Health and Road Safety, WRI Ross Center For Sustainable Cities, Washington DC, US Claudia works on a global strategy for addressing the public health impact of urban transportation and urban development. She has a background in the public sector in her home country of Peru. Tim Grandage, managing trustee, Future Hope, Kolkata, India Tim founded Future Hope, a charity that works with vulnerable children in Kolkata’s streets and slums, in 1987. Federico Cartin Arteaga, director, Rutas Naturbanas, San José, Costa Rica, @fedecartin Federico is an economist and urban planner. Rutas Naturbanas aims to revitalise urban rivers – to allow people to bike, walk and run – and eventually restore these water sheds. Alex Ross, director, World Health Organisation (WHO) Centre for Health Development (WHO Kobe Centre), Kobe, Japan, @directorwkc The WHO Kobe Centre has been working on urban health for over a decade, addressing health systems, health inequities and and urban planning-health collaboration. Alex’s background is in international development, with roles at USAid and DfID. Billie Giles-Corti, lead of the NHMRC Centre for Research Excellence in Healthy Liveable Communities, University of Melbourne, Melbourne, Australia, @billiegc Billie heads a centre with the mission to provide research that informs healthy urban design and planning. She is the author of a 2016 Lancet series on urban design, transport and health. Jess Beagley, policy research officer, NCD Alliance, London, UK, @JessicaBeagley Jess leads NCD Alliance’s work on environment and health, with a particular focus on urbanisation and climate change and the opportunities for co-benefit solutions to promote human and planetary health. The live chat is not video or audio-enabled but will take place in the comments section (below). Want to recommend someone for the panel or ask a question in advance? Get in touch via globaldevpros@theguardian.com or @GuardianGDP on Twitter. Follow the discussion using the hashtag #globaldevlive.


Sarasota, FL, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Heart Failure Software Market by Software Type (Knowledge-Based and Non-Knowledge Based) and by Delivery Mode (On-Premises, Web-Based and Cloud-Based Systems) for Hospitals and Others - Global Industry Perspective, Comprehensive Analysis and Forecast 2016 – 2022”.  According to the report, the global heart failure software market accounted for approximately USD 2.23 billion in 2016 and is expected to reach around USD 3.18 billion by 2022, growing at a CAGR of around 6.1% between 2017 and 2022. Congestive heart failure is a chronic condition that directly affects the pumping power of your heart muscles. CHF particularly refers the phase in which fluid increases around the heart and causes it force inefficiently. Rising necessity for continuous health assessment and dynamic advancements in technology is the major factor associated with heart failure software growth. In addition, clinical decision support system such as heart failure software system is continuously being used in the developed economies like the U.S., Germany, and France. Heart failure software facilitates management of cardiac patients safely and efficiently. It provides benefits patients in cardiac activity monitoring and analyzing risk zone of patients with cardiac diseases.  Browse through 42 Market Tables and 33 Figures spread through 110 Pages and in-depth TOC on “Global Heart failure software Market: By Type, Technology, Delivery Mode, Size, Share and Forecast 2016 – 2022”. Heart failure software market is driven mainly by increasing incidence of heart-related diseases across the different parts of the world. These diseases include angina pectoris, diabetes, hypertension etc. For instance, according to the International Diabetes Federation, China had the largest number of diabetic patients with around 96.2 million diabetic patients followed by India with around 66.8 million diabetic patients in 2014 which directly helped in fueling the heart failure software market. However, high costs or non-affordability of heart failure software are the key limitations which directly affects the growth of heart failure software market. Non-awareness and illiteracy among the population may directly affect the growth of heart failure software market. Advancement and innovation in technologies will boost the heart failure software market growth. Based on software type, the global market for heart failure software is classified into types: knowledge based and non-knowledge based. Global heart failure software market is dominated by knowledge-based software market. The knowledge-based software market is growing at the much faster rate in each year. The knowledge-based software will show more innovations and technological advances due to the demands by customers and medical professionals. Browse the full "Heart failure software Market by Software Type (Knowledge Based, Non-Knowledge Based,) and by Delivery mode (On-Premises, Web-Based and Cloud-Based Systems) for Hospitals and Others - Global Industry Perspective, Comprehensive Analysis and Forecast 2016 – 2022" report at https://www.zionmarketresearch.com/report/heart-failure-software-market Based on delivery mode, the global market of heart failure software market is classified into three types: on-premises, web-based and cloud-based systems. Globally, heart failure software market was dominated by cloud-based systems in 2016. This growth is attributed due to increasing prevalence of diabetes mellitus. Diabetes mellitus patient is at higher risk of heart failure followed by nondiabetes patients. This risk associated with blood viscosity, which is higher in diabetes mellitus patient. About 100,000 new cases of type 1 diabetes are diagnosed annually in North America.   Based on end-users, the global market of heart failure software market is classified into types: hospitals and others. Hospital segment dominated the end-users segment in 2016. This growth is attributed due to increasing adoption of electronic health records and remote patient monitoring system. Rising awareness about personal health amongst the population is expected to drive the growth of the consumer segment over the near future. Inquire more about this report @ https://www.zionmarketresearch.com/inquiry/heart-failure-software-market North America was the dominating region for heart failure software market in 2016. The growth was accredited to rising awareness amongst the population regarding the symptoms of heart diseases. Moreover, high-end research and technological advancements, increasing public interest are the important key factors which drive the demand of heart failure software market in this region. Higher healthcare expenditure in this region is important for the growth factors for heart failure software market. In 2014, the North American market for heart failure software was estimated more than USD 940 million and projected to reach approximately USD 1.40 billion in 2021 growing at a CAGR of around 7.0%. North America accounted for approximately more than 44% of total revenue of heart failure software market. In the European Union, there are approximately more than 31 million people living with diabetes aged between 20 and 79. This signifies an average diabetes prevalence rate of 8.6% of the adult population. This signifies the increasing market of heart failure software market in the EU. Europe was the second largest market for global heart failure software market in 2015 and it accounted for approximately USD 814.50 million in 2016. This growth is mainly associated with advancement in technological and healthcare research in this region. The Asia-Pacific region may offer significant opportunities for the heart failure software market during the forecast period. At present, China and India being the most populous countries in the region are contributing to the increase in demand for heart failure software market. China is a second largest economy after the U.S. is home to the world’s largest population with close to 1.4 billion inhabitants followed by India with approximately 1.2 billion people in 2014. Approximately 40-45% of the global heart disorder population lives in India and China which in turn provides significant opportunities for the global heart failure software companies to invest in this region. Growing cases of heart-related problem in the Middle East and Africa are also likely to fuel the growth of heart failure software market. In 2016 the Middle East and Africa accounted for approximately USD 78.50 million in terms of revenue. The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global heart failure software market include Cerner Corporation, 4S Information Systems Ltd., Axis Clinical Software, Inc., CitiusTech Inc., etc.     For more inquiry contact our sales team @ sales@zionmarketresearch.com This report segments the global heart failure software market as follows: Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.


Grant
Agency: Department of Health and Human Services | Branch: | Program: STTR | Phase: Phase II | Award Amount: 1.50M | Year: 2013

DESCRIPTION (provided by applicant): According to UnitedHealth14 by 2020 half of all Americans would have either diabetes or pre-diabetes with an annual cost of 500 billion - mainly attributed to diabetes related complications. Diabetes is a growing epidemic yet treatment goals are seldom achieved, and patients endure detrimental complications. In the US, 65% of all insulin takers (most of which have type-2 diabetes) have HbA1cgt7% and thus they are susceptible to complications. The challenge is that in reality insulin dosage is rarely titrate between clinic appointments27. Multiple studies with patients with type-2 and type-1 diabetes incorporating different insulin regimens showed frequent titration of insulin dosage is the key element to achieve therapygoal in the majority of patients2-10. Unfortunately, there is no single, patient-friendly, cost-effective, safe and effective intervention that provides frequent insulin titration to patients and maximizes the potential benefits of insulin therapy. Hygieia developed the Diabetes Insulin Guidance System (DIGS ) software (formerly called Private-Doc ) to automate the process of insulin dosage titration. The DIGS insulin adjustment software emulates the way clinicians evaluate and adjust dosage. The utilityof the DIGS software has been demonstrated in a prospective 16-week clinical trial during the Phase I STTR project12. In the Phase I study, the DIGS software titrated insulin therapy of 38 adults with type-1 and type-2 diabetes, on a weekly basis, resulting in improved glycolic control (lower HbA1c, mean glucose, and frequency of hypoglycemia). Hygieia further developed d-Nav, a handheld device, combining a glucose meter with the DIGS software that analyzes blood glucose patterns and periodically adjust theuser's insulin dosage. The goal is to have insulin takers use d-Nav instead of a glucose meter, at a similar cost and requiring no behavioral changes or increased testing frequency, leading to superior glycolic control. The d-Nav DIGS will be given to patients free of charge by their primary care physician (PCP), while the cost of consumable d-Nav glucose test strips is covered by medical insurance. In Phase II, Hygieia seeks to recruit [200] insulin treated patients in a prospective, open-label, randomized, controlled, multi-center, 6- month trial assessing the efficacy and safety of insulin therapy using d-Nav compared to a [smart] glucose meters in patients with type-2 diabetes. Upon enrollment patients will be randomized to either receive d-Nav or a [smart] glucose meter. Efficacy will be tested by attenuation in HbA1c and safety by the frequency and severity of hypoglycemia. The objectives are to establish clinical indication for registration and convince PCPs insulin therapy combined with d-Nav is safe and effective. We believe once d-Nav becomes widely available to insulin takers, optimization of insulin dosage will reduce incidence of diabetic complications and alleviate the health care system burden, thus saving billions of dollars in national health care costs. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: Despite immense effort to achieve balanced glucose control, millions of insulin-treated diabetic patients have high glucose levels and develop devastating complications at tremendousannual cost. Hygieia's DIGS software - now embedded in the d-Nav device - was previously proven, in a prospective study, capable of optimizing patient's insulin dosage leading to superior glycolic control12. The proposed study will test d-Nav's ability,as a single intervention compared to a [smart] blood glucose meter, to improve glycolic control for insulin takers, establishing it as the companion primary care physicians recommend to their insulin treated patients, thus leading to improved diabetes management, and reduced complications of the disease - saving billions of tax payer dollars in health care costs.


News Article | October 31, 2016
Site: www.PR.com

JumFit, a unique UAE-based web platform and app, aims to revolutionize corporate wellness services by powering them with Artificial Intelligence. Dubai, United Arab Emirates, October 31, 2016 --( JumFit’s services include the following: 1. Helping companies analyze their wellness needs. 2. Helping individuals benefit from the incentives provided by their companies. 3. Designing programs encompassing wellness, health, engagement, gamification and team building initiatives. 4. Providing organizations with analytics that is vital to measuring the Return on Employee Investment through corporate wellness programs. 5. Integrating many solution providers into a single platform and giving organizations the opportunity to make choices based on their budgets, needs and the type of corporate culture they would like to drive. JumFit’s corporate wellness AI powered platform aims to bring all this and more under its umbrella so that organizations can truly manage and administer every option available year round without taking the stress of engaging with different service providers. With the help of this platform, organizations will be able to access macro data (without compromising individual privacy) regarding health issues and engagement rates within the company. This will then help them chart a course of action to take towards re-engaging their employees and encouraging them towards adopting a healthier lifestyle. With the increasing number of heart diseases, numerous cases of hypertension, diabetes and high obesity rates among adults, employee wellness has become a vital issue in today’s world, especially in the UAE. According to the data published by the International Diabetes Federation in November 2014, 1 in 5 people in the UAE are diabetic, with 60% of the population being obese. Smoking, obesity and bad lifestyle habits cause cardiovascular diseases, hypertension and heart attacks; with cardiovascular disease being the leading cause of death worldwide today. Hypertension and high blood pressure affects one in three people globally, but in most cases it might go undetected for many years due to the lack of visible symptoms. Diabetes can also go hidden for years. Being overweight at a young age can lead to diabetes years later. Early detection and awareness, healthy food, cessation of smoking, regular exercises and other lifestyle changes can help combat the risks associated with these diseases. Employers can contribute a lot towards this through wellness programs at the workplace. This is very important as healthy people usually work more productively and are more engaged as compared to those who have health issues. Poor staff management and communication can also be the reason behind employee disengagement. A study by Gallup conducted three years ago, estimates that 74% of the workforce in the UAE is disengaged at work. The less motivated the employees are, the lower their performance levels are likely to be. Salary hikes or financial incentives alone cannot solve the problem of employee disengagement. Companies should rethink the way they manage and treat their employees so that they feel rewarded and taken care of. This does not merely involve implementing a health and fitness program. Ensuring employee wellness and engagement should be a continuous process. Each step the company takes towards achieving it should be carefully evaluated and analyzed for its effectiveness. It is this goal that JumFit helps its corporate customers achieve. JumFit provides a holistic solution that can be evaluated from time to time with the aid of modern technology. Backed by machine learning and artificial intelligence, JumFit’s wellness solution makes sure that every company it caters to, gets its own tailor made program which is frequently evaluated and improved as per its changing demands, obtained results and feedback. Soon after the launch of JumFit corporate wellness platform, the team will be launching the JumFit app. Both the platform and the app will be free of charge to organizations and app users. Also, the JumFit team will be attending the Sun & Sand Sports Fitness Fest along with their diagnostics partner, Eastern Biotech & Life Sciences. Those interested can meet them there on the 4th and 5th of November, 2016 at The Palm, Skydive Dubai. For more information, please visit https://jumfit.com. Dubai, United Arab Emirates, October 31, 2016 --( PR.com )-- JumFit, a startup in the field of corporate wellness and employee engagement in the United Arab Emirates redefines corporate wellness services with the aid of big data analytics and artificial intelligence. In collaboration with a number of partners such as clinics, health clubs, trainers, dietitians and many others, the team delivers the most comprehensive employee engagement and wellness platform in the UAE. As the partners are integrated well into the program, organizations can avail the services of each provider without having to manage them separately. JumFit’s wellness solution suite focuses not only on implementing a holistic wellness program tailored to an organization’s needs but also on continually analyzing the results so as to improve the effectiveness of the program.JumFit’s services include the following:1. Helping companies analyze their wellness needs.2. Helping individuals benefit from the incentives provided by their companies.3. Designing programs encompassing wellness, health, engagement, gamification and team building initiatives.4. Providing organizations with analytics that is vital to measuring the Return on Employee Investment through corporate wellness programs.5. Integrating many solution providers into a single platform and giving organizations the opportunity to make choices based on their budgets, needs and the type of corporate culture they would like to drive.JumFit’s corporate wellness AI powered platform aims to bring all this and more under its umbrella so that organizations can truly manage and administer every option available year round without taking the stress of engaging with different service providers. With the help of this platform, organizations will be able to access macro data (without compromising individual privacy) regarding health issues and engagement rates within the company. This will then help them chart a course of action to take towards re-engaging their employees and encouraging them towards adopting a healthier lifestyle.With the increasing number of heart diseases, numerous cases of hypertension, diabetes and high obesity rates among adults, employee wellness has become a vital issue in today’s world, especially in the UAE. According to the data published by the International Diabetes Federation in November 2014, 1 in 5 people in the UAE are diabetic, with 60% of the population being obese. Smoking, obesity and bad lifestyle habits cause cardiovascular diseases, hypertension and heart attacks; with cardiovascular disease being the leading cause of death worldwide today. Hypertension and high blood pressure affects one in three people globally, but in most cases it might go undetected for many years due to the lack of visible symptoms. Diabetes can also go hidden for years. Being overweight at a young age can lead to diabetes years later. Early detection and awareness, healthy food, cessation of smoking, regular exercises and other lifestyle changes can help combat the risks associated with these diseases. Employers can contribute a lot towards this through wellness programs at the workplace. This is very important as healthy people usually work more productively and are more engaged as compared to those who have health issues.Poor staff management and communication can also be the reason behind employee disengagement. A study by Gallup conducted three years ago, estimates that 74% of the workforce in the UAE is disengaged at work. The less motivated the employees are, the lower their performance levels are likely to be. Salary hikes or financial incentives alone cannot solve the problem of employee disengagement. Companies should rethink the way they manage and treat their employees so that they feel rewarded and taken care of. This does not merely involve implementing a health and fitness program. Ensuring employee wellness and engagement should be a continuous process. Each step the company takes towards achieving it should be carefully evaluated and analyzed for its effectiveness. It is this goal that JumFit helps its corporate customers achieve.JumFit provides a holistic solution that can be evaluated from time to time with the aid of modern technology. Backed by machine learning and artificial intelligence, JumFit’s wellness solution makes sure that every company it caters to, gets its own tailor made program which is frequently evaluated and improved as per its changing demands, obtained results and feedback.Soon after the launch of JumFit corporate wellness platform, the team will be launching the JumFit app. Both the platform and the app will be free of charge to organizations and app users.Also, the JumFit team will be attending the Sun & Sand Sports Fitness Fest along with their diagnostics partner, Eastern Biotech & Life Sciences. Those interested can meet them there on the 4th and 5th of November, 2016 at The Palm, Skydive Dubai.For more information, please visit https://jumfit.com. Click here to view the list of recent Press Releases from Obocart FZC


News Article | December 6, 2016
Site: www.marketwired.com

BROSSARD, QUEBEC--(Marketwired - Dec. 6, 2016) - DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in applying Artificial Intelligence in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today a pilot project contract for diabetic macular edema and diabetic retinopathy screening with BAYER Canada. Under the terms of the agreement, DIAGNOS will provide a fully turn-key screening service to benefit one thousand diabetic patients in the Toronto area. Screening will be offered to diabetics affiliated to their health entities to test the impact of including preventive screening programs. According to the International Diabetes Federation, diabetic retinopathy and macular edema are the most common diabetic eye diseases and the leading cause of blindness around the world. It is a treatable disease that, as with most diseases, has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to more severe stages, making early detection methods critical by helping the prevention of vision loss. "The opportunity to partner with Bayer offers an immense advantage at detecting treatable diabetic retinopathy using the advanced Artificial Intelligence technology and eliminating sight-threatening complications of this disease", said Netan Choudhry, MD FRCS(C) DABO, director at DIAGNOS. Mr. André Larente, President of DIAGNOS, added "We are excited to start our new commercial relationship with BAYER in Canada and begin screening for diabetic macular edema and retinopathy. Following the expected success of this project, we intend to expand the scope of services offered through this pharmaceutical company into other countries." Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources. This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, please visit our website at www.diagnos.com, or visit the SEDAR website at www.sedar.com.

Loading International Diabetes Federation collaborators
Loading International Diabetes Federation collaborators